Research programme: RNA interference-based therapeutics - RXi Pharmaceuticals

Drug Profile

Research programme: RNA interference-based therapeutics - RXi Pharmaceuticals

Alternative Names: Anti-CTFG RNAi therapy; Anti-VEGF sd-rxRNA; RXI-762; RXI-804; rxRNA®; rxRNAori®; sd-rxRNA®; Self-delivering RNAi compounds - RXi Pharmaceuticals

Latest Information Update: 28 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RXi Pharmaceuticals Corporation
  • Developer RXi Pharmaceuticals; RXi Pharmaceuticals Corporation; University of Massachusetts Medical School
  • Class Antineoplastics; Skin disorder therapies; Small interfering RNA; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors; Programmed cell death-1 receptor antagonists; RNA interference; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Eye-Disorders; Skin disorders

Highest Development Phases

  • Preclinical Cancer
  • No development reported CNS disorders; Eye-Disorders; Inflammation; Metabolic disorders; Obesity; Respiratory tract disorders; Retinal disorders; Rheumatoid arthritis; Skin disorders
  • Discontinued Cytomegalovirus retinitis

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for research development in Skin-disorders in USA
  • 02 Aug 2018 RXi Pharmaceuticals has patent protection for sd-rxRNA platform in European Union and Japan
  • 11 May 2018 RXi Pharmaceuticals and Iovance Biotherapeutics agree to co-develop sd-rxRNA® therapeutics and TIL autologous cell therapy for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top